Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 16/20 | 0.69 |
| ▸ | MAPT | P10636 | 13/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 11/20 | 0.69 |
| ▸ | TP53 | P04637 | 8/20 | 0.69 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 15/20 | 0.53 |
| ▸ | GFER | P55789 | 3/20 | 0.53 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 10/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.52 |
| ▸ | NFKB1 | P19838 | 3/20 | 0.52 |
| ▸ | NFKB2 | Q00653 | 3/20 | 0.52 |
| ▸ | RELA | Q04206 | 3/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 5/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.49 |
| ▸ | CASP3 | P42574 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 4/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28701725 | 0.86 | HDAC6 (0.54) | RAB9AMAPTSMN1; SMN2TP53NPC1 | |
| SCHEMBL28698102 | 0.86 | MAPT (0.50) | RAB9AMAPTSMN1; SMN2TP53NPC1 | |
| SCHEMBL29479691 | 0.86 | HDAC6 (0.54) | RAB9AMAPTSMN1; SMN2TP53NPC1 | |
| SCHEMBL23033654 | 0.84 | MAPT (0.54) | RAB9AMAPTSMN1; SMN2TP53NPC1 | |
| SCHEMBL23034143 | 0.83 | MAPT (0.71) | RAB9AMAPTSMN1; SMN2TP53NPC1 | |
| SCHEMBL12942543 | 0.81 | RAB9A (1.00) | RAB9AMAPTSMN1; SMN2TP53PIK3CB | |
| SCHEMBL23012747 | 0.81 | MAPT (0.46) | RAB9AMAPTSMN1; SMN2TP53NPC1 | |
| SCHEMBL29479793 | 0.81 | KMT2A (0.48) | RAB9AMAPTSMN1; SMN2TP53NPC1 | |
| SCHEMBL28695332 | 0.81 | KMT2A (0.48) | RAB9AMAPTSMN1; SMN2TP53NPC1 | |
| SCHEMBL29479781 | 0.81 | MAPT (0.46) | RAB9AMAPTSMN1; SMN2TP53NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240092768-A1 | CRYSTAL FORM OF ANTI-INFLUENZA VIRUS COMPOUND, PREPARATION METHOD FOR CRYSTAL FORM, AND USE OF CRYSTAL FORM | XIZANG HAISCO PHARMACEUTICAL CO., LTD. (CN) | 2024-03-21 | — | — | US | disclosed |
| US-20240043416-A1 | SALT AND CRYSTAL FORM OF HA INHIBITOR COMPOUND | SICHUAN HAISCO PHARMACEUTICAL CO., LTD. (CN) | 2024-02-08 | — | — | US | disclosed |
| EP-4289826-A1 | SALT AND CRYSTAL FORM OF HA INHIBITOR COMPOUND | Sichuan Haisco Pharmaceutical Co., Ltd. (CN) | 2023-12-13 | — | — | EP | disclosed |
| EP-4282860-A1 | CRYSTAL FORM OF ANTI-INFLUENZA VIRUS COMPOUND, PREPARATION METHOD FOR CRYSTAL FORM, AND USE OF CRYSTAL FORM | Sichuan Haisco Pharmaceutical Co., Ltd. (CN) | 2023-11-29 | — | — | EP | disclosed |
| CN-116761605-A | Salts and crystalline forms of HA inhibitor compounds | 四川海思科制药有限公司 | 2023-09-15 | — | — | CN | disclosed |
| CN-116670132-A | Crystal form of anti-influenza virus compound, preparation method and application thereof | 四川海思科制药有限公司 | 2023-08-29 | — | — | CN | disclosed |
| WO-2022156737-A1 | CRYSTAL FORM OF ANTI-INFLUENZA VIRUS COMPOUND, PREPARATION METHOD FOR CRYSTAL FORM, AND USE OF CRYSTAL FORM | 四川海思科制药有限公司 | 2022-07-28 | — | — | WO | disclosed |
| WO-2022156737-A1 | CRYSTAL FORM OF ANTI-INFLUENZA VIRUS COMPOUND, PREPARATION METHOD FOR CRYSTAL FORM, AND USE OF CRYSTAL FORM | 四川海思科制药有限公司 | 2022-07-28 | — | — | WO | disclosed |
| CN-114269725-A | Anti-influenza virus compound and preparation method and application thereof | 四川海思科制药有限公司 | 2022-04-01 | — | — | CN | disclosed |
| WO-2021032209-A1 | ANTI-INFLUENZA VIRUS COMPOUND, PREPARATION METHOD AND USE THEREOF | 四川海思科制药有限公司 | 2021-02-25 | — | — | WO | disclosed |
| WO-2021032209-A1 | ANTI-INFLUENZA VIRUS COMPOUND, PREPARATION METHOD AND USE THEREOF | 四川海思科制药有限公司 | 2021-02-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240092768-A1 | CRYSTAL FORM OF ANTI-INFLUENZA VIRUS COMPOUND, PREPARATION METHOD FOR CRYSTAL FORM, AND USE OF CRYSTAL FORM | ZC3HAV1, ZC3HAV1L, FMNL1 | RAB9A 1552/4885MAPT 1387/4885SMN1; SMN2 4781/4885 |
| US-20240043416-A1 | SALT AND CRYSTAL FORM OF HA INHIBITOR COMPOUND | MMP11, MMP1, MMP2 | RAB9A 1816/4885MAPT 2436/4885SMN1; SMN2 4860/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.